Cytokinetics Announces Oral Bioavailability Results For CK-1827452
Sat, 02 Dec 2006 08:00 AM EST
... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that the results from an oral bioavailability study evaluating CK-1827452, a novel cardiac myosin activator, in healthy volunteers support advancement of an oral formulation of CK-1827452 into Phase II clinical trials. [click link for full article] ...
Related Topics
- CK
- CK-MB
- Oral Cancer
- Oral Health
- Amoxicillin Oral Suspension
- Zidovudine Oral Syrup
- Bismuth Subsalicylate Oral Liquid
- Sumatriptan Oral
- Ergocalciferol, Vitamin D2 Oral Solution
- Stavudine Oral Solution
- Metronidazole Oral
- Erythromycin Oral Suspension
- Fluconazole Oral
- Terbinafine Oral
- Methadone Oral
- Mesoridazine Oral Concentrate
- Pseudoephedrine and Hydrocodone
- Mycophenolate Oral
- Betaxolol Oral
- Levofloxacin Oral

Not Signed In -


